Nanoflex Robotics Lands €12.5M EIC Funding for Medical Robotics

Nanoflex Robotics AG is set to accelerate the commercialization of its advanced endovascular intervention system following a significant funding award from the European Innovation Council (EIC) Accelerator. The prestigious program has committed a total of €12.5 million in blended financing, comprising a €2.5 million grant and a substantial €10 million equity investment from the EIC Fund. This backing positions the Swiss medtech firm to advance its mission of democratizing access to critical vascular treatments.

The EIC Accelerator's rigorous selection process identified only 38 companies from approximately one thousand applicants across Europe. Nanoflex Robotics stood out as one of just four Swiss entities to receive this distinction, and notably, the sole representative from the medical technology sector. This achievement underscores the disruptive potential of their magnetically controlled telerobotic platform.

At its core, Nanoflex Robotics is developing a novel robotic solution designed to overcome the physical limitations hindering widespread adoption of endovascular procedures, particularly in treating conditions like stroke. The system employs magnetic navigation to precisely guide ultra-flexible guidewires through the intricate network of blood vessels. This innovative approach promises to enhance procedural speed and safety, paving the way for remote, teleoperated interventions that can extend specialist care beyond major urban centers.

The infusion of capital will be instrumental in enabling Nanoflex Robotics to complete crucial clinical validation studies required for CE marking in the European market. Furthermore, it will support the successful launch of the initial commercial iteration of their groundbreaking platform. This strategic funding aligns with the growing global demand for minimally invasive surgical techniques, a market segment projected to experience robust expansion in the coming years, driven by an aging population and advancements in robotic surgery.

Matt Curran, CEO of Nanoflex Robotics, expressed enthusiasm for the award, stating, “This funding represents a pivotal moment in our journey to expand clinical validation and a powerful validation of our team, technology, and vision. Our unique electromagnetically controlled robotic platform offers superior navigation speed and accuracy compared to existing devices. We are honored by the EIC’s confidence and support, which strongly affirms our commitment to bridging the treatment access gap between rural and urban populations.”

The EIC Accelerator's investment in Nanoflex Robotics highlights a broader trend of increased European Union support for deep-tech innovations with significant societal impact. By backing companies like Nanoflex, the EIC aims to foster a more competitive European innovation ecosystem and translate cutting-edge research into tangible healthcare solutions. The successful deployment of this technology could significantly alter treatment paradigms for vascular diseases, potentially saving countless lives and reducing long-term healthcare costs.